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Some antihypertensive drugs have also renoprotective and anti-inﬂammatory properties that go beyond their eﬀect on blood
pressure. It has been suggested that microalbuminuria and glomerular ﬁltration rate (GFR) are associated with circulating levels of
the soluble form of the receptor, sRAGE (soluble receptor for advanced glycation ends-products). In the present analysis, we used
data from the TALENT study to evaluate soluble receptor for advanced glycation end-products (sRAGE) plasma levels in patients
with hypertension and high-cardiovascular risk-treated nifedipine and telmisartan in combination. Treatment with nifedipine-
telmisartan signiﬁcantly decreased mean systolic and diastolic ambulatory blood pressure and resulted in a signiﬁcant increase
in sRAGE plasma concentrations after 24 weeks of therapy. We concluded that in hypertensive patients with early-stage renal
disease, sRAGE concentrations are not inﬂuenced by either microalbuminuria or GFR. Long-term treatment with a combination
of nifedipine-telmisartan may have a beneﬁcial eﬀect increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-
inﬂammatory activity.
1.Introduction
Atherosclerosis has been regarded recently as an inﬂamma-
tory disease. Most cardiovascular risk factors are associated
with enhanced vascular inﬂammatory state [1]. Among
these, hypertension has been suggested to have a proin-
ﬂammatory action by inducing endothelial expression of
cytokines [2]. C-reactive protein (CRP), leukocyte adhesion
molecules,chemotacticandpro-inﬂammatorycytokinesand
heat shock proteins were found to be increased in patients
with essential hypertension [3, 4]. Hypertension and cardio-
vascular disease (CVD) are intimately connected to chronic
kidney disease (CKD) [5]. High blood pressure has also been
associated with the development of end-stage renal disease
[6]. On the other hand, atherosclerosis, considered one of
the traditional risk factors for CVD, is more prevalent in
CKD patients, at any stage, than in the general population
[7]. Several observational studies have suggested that some
antihypertensive drugs such as the inhibitors of the renin-
angiotensin system (RAS) or dihydropyridine-based calcium
antagonists promote normal endothelial function, thus
showing anti-inﬂammatory activity [8, 9]. Due to this spe-
ciﬁcanti-inﬂammatory property, the RAS blockade canexert
another eﬀect, independently of its hemodynamic action,
namely,thereductionofthedevelopmentandprogressionof
kidney disease [10]. In the setting of nephroprotection, the2 Mediators of Inﬂammation
beneﬁcial eﬀect of counteracting the RAS system has been
suggested to be due, at least in part, to the modulation of
the interaction between the receptor for advanced glycation
end products (RAGE) and its ligands [11]. RAGE is a multi-
ligand member of the immunoglobulin superfamily of cell
surface molecules, which was ﬁrst described as a receptor
f o ra d v a n c e dg l y c a t i o ne n dp r o d u c t s( A G E s )[ 12, 13]. AGEs
have a proinﬂammatory action, and have been related to
endothelial dysfunction, arterial stiﬀening and hypertension
[14]. Furthermore, the interaction between RAGE and its
ligands is intimately involved in the pathobiology of a wide
range of diseases that share common features, such as en-
hanced oxidative stress, immune/inﬂammatory responses,
and impaired cell functions [15]. RAGE has a secreted
isoform, termed soluble RAGE (sRAGE) that lacks the trans-
membrane anchoring domain and therefore circulates in
plasma. Soluble RAGE has AGE-binding properties and acts
as a scavenger receptor, preventing the generation of the
signalling cascade usually associated with RAGE, thus acting
as an inhibitor of AGE-mediated eﬀects [16]. High plasma
levels of sRAGE have been reported to be associated with
a lower incidence of coronary artery disease (CAD) [17],
and low plasma levels of sRAGE have been reported in
patients with carotid and femoral atherosclerosis as well as
those with metabolic syndrome [18]. Recently, it has been
foundthatsRAGEcorrelateswiththeextentof24-houralbu-
min excretion, conﬁrming the involvement of the RAGE-
ligand axis in the development of diabetic nephropathy
[19]. Nevertheless this correlation has not been conﬁrmed
by subsequent studies on patients with normal values of
glomerular ﬁltration rate (GFR) and therefore the role of
sRAGE in the setting of early-stage renal disease has not been
fully elucidated [20]. Moreover, a number of drugs recently
proved to be able to modulate sRAGE levels [21].
Theaimsofthepresentstudywere(1)tostudytheassoci-
ationbetweensRAGEandmicroalbuminuriainhypertensive
patients at high cardiovascular risk and (2) to evaluate the
eﬀect of treatment with telmisartan and nifedipine, which
are antihypertensive drugs with speciﬁc anti-inﬂammatory
eﬀect, on sRAGE levels according to the presence or absence
of microalbuminuria.
2. Methods
2.1. Study Population. Participants were derived from the
TALENT study (multicenter study evaluating the Eﬃcacy of
nifedipine GITS-telmisartan combination in blood pressure
control and beyond). TALENT was a multicenter random-
ized double-blind prospective parallel group (3-arms) trial.
It was approved by Ethics Committees/Institutional Review
Boards of the centers involved and was conducted according
to Good Clinical Practice and under the guiding principles
of the Declaration of Helsinki. All individuals provided their
informed consent to participate. Included were men and
women aged 18–75 years whose oﬃce systolic blood pressure
was higher than 135mmHg and with one or more of the
following cardiovascular risk factors: type 2 diabetes mellitus
(fasting blood glucose ≥126mg/dL or history of antidia-
betic drug use), microalbuminuria, electrocardiographic or
echocardiographic evidence of left ventricular hypertrophy
and metabolic syndrome. The protocol details and main
study results are published elsewhere [22]. Patients with a
history of stroke, a transient ischemic attack or myocardial
infarction within the previous 12 months, those on angiot-
ensin receptor antagonist or calcium antagonist and those
with renal failure (serum creatinine >2mg/dL)ormacroal-
buminuria were excluded from the study. Patients were
randomized to one of the following treatment groups in a
2:1:1 ratio: group A received the combination of nifedipine
GITS 20mg/telmisartan 80mg per day; group B received
monotherapy with nifedipine GITS 20mg/day; group C
received monotherapy with telmisartan 80mg/day. After 8
weeks of treatment, all the 2 monotherapy groups were
switched to the combination (telmisartan 80mg-nifedipine
GITS 20mg per day). From week 16 to week 24, patients
were allowed to continue the combination treatment for an
additional 8 weeks with the option to uptitrate nifedipine
GITS to 30mg.
To limit any potentially confounding eﬀects due to out-
lying values, we chose to exclude from our analysis subjects
with any CRP values >10mg/L. We also excluded those with
missing serum biomarkers or microalbuminuria analyses at
any of the study visit.
2.2. Methods. Frozen blood sample from baseline, 16 and
24 weeks, were simultaneously analyzed at a core facility. As
in previous clinical studies involving total sRAGE (esRAGE
plus cRAGE), we determined plasma sRAGE levels using
a commercially available ELISA kit (Quantikine; R&D sys-
tems) according to the manufacturer’s instructions. Brieﬂy, a
monoclonal anti-sRAGE antibody was used to bind plasma
sRAGE, and bound sRAGE detected with a horseradish-
peroxidase-linked polyclonal antibody speciﬁc for the extra-
cellular domain of RAGE. After washing, a hydrogen perox-
ide solution was added to each well, and optical density at
450nm was determined with a microplate reader (Multiscan
Ex, Thermolabsystems). The intraassay and inter-assay coef-
ﬁcients of variation values were 6% and 8%, respectively and
the minimum detectable dose of RAGE ranged from 1.23–
16.14pg/mL. The presence/absence of microalbuminuria
was detected by local laboratories by the CLINITEK Status
Analyzer, Siemens. GFR was estimated using the Modiﬁca-
tion of Diet in Renal Disease Study equation, equation 7,
derived by Levey et al. [23].
All measurements were performed without knowledge of
the treatment assignment.
2.3. Statistic. Continuous data are reported as mean ± SD
along the paper, even in included tables, if the data were
skewed. Categorical data are presented as per group percent-
ages. Diﬀerences between subgroups were evaluated using
Student’st-testforthenormallydistributedones.Ifdatawere
skewed, the logarithmic transformation was done to make
the data valid for Student’s t-test. Diﬀerences in categorical
data were compared using the chi-square test. Simple
(univariate) linear regression model was adopted to analyze
the association of sRAGE with GFR. A two-tailed P valueMediators of Inﬂammation 3
less than 0.05 was considered to be statistically signiﬁcant.
The relationship between two variables was tested using the
Pearson’s correlation coeﬃcient.
3. Results
Among the 405 subjects included in the TALENT study,
inﬂammatory markers and microalbuminuria data were
available for 262 patients (173 males and 89 females, mean
age 59±9 years).Amongthosepatients,99(38%)hadapos-
itive result at the microalbuminuria test (30–300mg/24h),
while the remaining 163 (62%) had a negative result
(<30mg/24h). The mean GFR value of our cohort at the
recruitment was 93 ± 23mL/min.
No signiﬁcant diﬀerences were found in plasma sRAGE
levels concerning sex of the participants (141pg/mL versus
138pg/mL, P = ns), according to the diabetic (134pg/mL
versus 152pg/m) and smoking status (139pg/mL versus
142pg/mL, P = ns) or statin use (145pg/mL versus
140pg/mL, P = ns). The log-transformed sRAGE levels
showed a positive correlation with serum creatinine (r =
0.14, P = 0.0059) and uric acid (r = 0.122, P = 0.016),
but were not signiﬁcantly correlated with systolic or diastolic
blood pressure (r = 0.09 and r =− 0.05, P = ns), GFR
(r =− 0.07, P = ns), and hsCRP (r = 0.05, P = ns) in the
entire study cohort.
Baseline characteristics of the patients, according to the
presence/absence of microalbuminuria are listed in Table 1.
As shown in the Table 1, patients with and without microal-
buminuria were similar with respect to age, sex, blood pres-
sure, lipid proﬁle, and GFR values. Plasma concentrations
of sRAGE were similar between the two groups. Of interest,
baseline plasma concentration of sRAGE was not associated
with GFR (r =− 0.08, P = ns), both in patients with (r =
0.11, P = ns) and without microalbuminuria (r =− 0.06,
P = ns).
After 16 weeks of telmisartan-nifedipine treatment ac-
cording to the study protocol, a signiﬁcant reduction in
ambulatory blood pressure was observed: 24-h mean systolic
blood pressure decreased from 137 ± 5mmHg to 126 ±
5mmHg (P<0.001), and diastolic blood pressure decreased
from 82 ± 5mmHg to 75 ± 5mmHg (P<0.001). At that
time point, the percentage of patients with microalbumin-
uria decreased from 38% to 29% (P<0.001), and a trend
towards an increase in sRAGE plasma concentration was
observed (P = ns).
After other 8 weeks of treatment with the combina-
tion telmisartan-nifedipine, the percentage of patients with
microalbuminuria decreased to 28% (P<0.01 from base-
line).Treatmentwithtelmisartan-nifedipineresultedinasig-
niﬁcant increase in sRAGE values as compared with baseline
(log-transformed sRAGE 5.16 ± 0.6v e r s u s5 .13 ± 0.6, P<
0.05). A similar increase in sRAGE plasma concentrations
was found in patients with and without microalbuminuria
(0.03 ±0.2v e r s u s0 .05 ±0.2 P = ns).
Furthermore, we studied the relationship between the
change in sRAGE values and ambulatory blood pressure
from baseline to week 24. We observed that the increase in
logtransformedsRAGEconcentrationswasnotproportional
Table 1: Baseline characteristics of patients with and without mi-
croalbuminuria. Continuous data are reported as mean ± SD or











Age, years 60 ±10 58 ±10 ns
Males 62% 68% ns
Diabetes mellitus 59% 61% ns
Mean 24-h SBP,
mmHg 137 ±5 136 ±5n s
Mean 24-h DBP,
mmHG 84 ±58 5 ±5n s
Total cholesterol,
mmol/L 5.06 ±0.96 5.14 ±1.14 ns
HDL cholesterol,
mmol/L 1.24 ±0.31 1.21 ±031 ns
LDL cholesterol,
mmol/L 3.1 ±0.85 3.15 ±1.01 ns
Triglycerides,
mmol/L 1.74 ±1.11 .65 ±0.95 ns
Body mass index,
Kg/m2 29 ±32 9 ±3n s
Smokers, % 56% 48% ns
Creatinine, μmol/L 82.2 ±19.48 2 .2 ±19.4n s
GFR mL/s/1.73m2 1.55 ±0.38 1.57 ±0.45 ns
Log-transformed




sure, as shown in Figure 1.
4. Discussion
According to the 2010 United States Renal Data System
report, CKD patients, with any stage of CKD, have higher
rates of hypertension, and the prevalence of hypertension
increases with the stage of kidney disease [24]. Cardiovas-
cular disease, as well, is tightly bound to impairment of
kidney function, as demonstrated by Anavekar and col-
leagues in the VALIANT study, being the risk of death from
any cardiac event inversely associated with the glomerular
ﬁltration rate, making even mild kidney dysfunction a
major unconventional risk factor for cardiovascular com-
plications [25]. RAGE signalling has been suggested to
play a pivotal role in inducing inﬂammatory process and
endothelial dysfunction, that characterize both diabetic and
nondiabetic atherosclerosis and its clinical manifestations
[15]. Microalbuminuria, which is an independent risk factor
for renal and cardiovascular disease, is a feature of hyper-
tension, metabolic syndrome, and type I diabetes mellitus
and is supposed to be associated with higher values of
sRAGE [19, 26]. In a subanalysis of the TALENT study,
we found that the presence of microalbuminuria does not4 Mediators of Inﬂammation
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Figure 1: Log-transformed sRAGE by 24 hour systolic (a) and dias-
tolic (b) blood pressure change from baselin at week 24.
aﬀect baseline sRAGE plasma concentrations. Furthermore,
antihypertensivetreatmentwiththecombinationnifedipine-
telmisartan increased sRAGE values regardless of the pres-
ence of microalbuminuria. Even if the TALENT study was
not designed to evaluate eﬀect of the intervention on sRAGE
levels, we can hypothesize that this is related to a speciﬁc
eﬀect of nifedipine-telmisartan on endothelial function.
Angiotensin II activates NAD(P)H oxidase which stimu-
lates the production of reactive oxygen species; this increases
the function of the proinﬂammatory transcription factor
nuclear factor-κB which controls the expression of proin-
ﬂammatory cytokines. Angiotensin II also stimulates growth
factors, extracellular matrix protein synthesis, and matrix
metalloproteinases, thereby promoting proliferative and ﬁ-
brotic mechanisms involved in vascular remodelling. Telmis-
artan has an additional speciﬁcity of action that relates to a
partial peroxisome proliferator-activated receptor-γ (PPAR-
γ)agonism.Invitrostudieshaverecentlyshownthatthrough
this peculiar function of PPAR-γ, telmisartan inhibits super-
oxide generation and monocyte chemoattractant protein-1
(MCP-1) gene expression in mesangial cells, thus exerting
an anti-inﬂammatory activity against AGE-mediated kidney
damage [27].
Long-acting CCBs exert antioxidant eﬀects that protect
LDL and membrane lipids from oxidation, this eﬀect being
independent of calcium channel modulation [9]. It has been
foundthatnifedipineinhibitstheTNF-α-inducedgeneration
of reactive oxygen species and the subsequent MCP-1 and
VCAM-1 expression in human cultured endothelial cells by
suppressing NADPH oxidase activity. Furthermore, nifedip-
ine is known not only to upregulate endothelial nitric oxide
synthase expression, but also to increase NO bioactivity via
superoxide dismutase induction in endothelial cells [28].
As a consequence, both telmisartan and nifedipine share
the potential to exert speciﬁc anti-inﬂammatory actions that
go beyond their class eﬀects. Evidences from preclinical and
clinical studies suggest that the complementary mechanisms
of action of these drugs provide greater eﬃcacy when used
in combination. TALENT conﬁrms that the duration of
treatment is a key factor: as a matter of fact, the increase in
sRAGE was signiﬁcant only after 24 weeks of treatment
whereas blood pressure reduction was already evident after
two weeks [22].
OurobservationofasigniﬁcantincreaseinsRAGEvalues
during nifedipine-telmisartan treatment corroborates the
possible role of these drugs in inﬂuencing RAGE-ligands
signaling as already shown also in other studies [27, 29]. The
biological consequence of an increased amount of endoge-
nous sRAGE is an anti-inﬂammatory and antithrombotic
eﬀect. Interactions between RAGE and its ligands result
in enhanced transcription and production of various pro-
inﬂammatory mediators via activation of nuclear factor-
κB.TheseRAGE-dependentpro-inﬂammatorygenesinclude
intracellular adhesion molecule-1 (ICAM-1), VCAM-1, E-
selectin, TNF-α, interleukin-1, interleukin-6, and cyclo-
oxygenase-2. Therefore, ligand-RAGE binding is thought to
be involved in the formation, progression, and instability of
atheroscleroticplaqueswithsubsequentmacrovascularcom-
plications. Since sRAGE is the circulating isoform of RAGE
which has been identiﬁed and theorized to competitively
prevent the binding of AGEs to the transmembrane form
of RAGE, drugs that increase sRAGE plasma concentrations
may have the eﬀect of attenuating atherosclerosis. This
hypothesis has been supported by animal models in which
administration of sRAGE to mice retarded the progression of
atherosclerosis [30].
Microalbuminuriaisamarkerofmicrovascularendothe-
lial dysfunction, and reduction of microalbuminuria could
reﬂect a better haemodynamic situation, namely, a decreased
shear stress, that ameliorates the endothelial performance
and modiﬁes sRAGE levels, thus reducing the cardiovascular
risk [31]. In the TALENT study, we found that sRAGE
plasma levels were not aﬀected by the presence or absence
of microalbuminuria. Our data are consistent with previous
observations on diabetic Chinese patients with early stage-
renaldisease[32].Onthecontrary,inpatientswithadvanced
degreeofkidneydysfunction,documentedbyareducedGFR
and sRAGE concentrations were found to be positively asso-
ciated with increased 24-hour albumin excretion [33]. The
mean value of GFR in our study population was 93mL/min,
conﬁrming that our patients can be considered at an early
stage of renal disease, since patients with elevated creatinine
plasma levels and those with macroalbuminuria (spot urine
albumin/creatinine ratio >300mg/g) were excluded from
the study. Therefore, the apparent discrepancies betweenMediators of Inﬂammation 5
the studies could be explained by the diﬀerent severity of
renal impairment.
Our study did not ﬁnd any associations between sRAGE
and GFR values. A recent study by Basta and colleagues
identiﬁed a GFR of approximately 60mL/min as a threshold
below which sRAGE accumulates [34]. Thus, the lack of
association between GFR and sRAGE plasma levels in our
studycouldbeexplainedbytheGFRhigherthan90mL/min.
The role of calcium antagonists on the kidney with
previous formulations of the drugs [35, 36]h a sb e e nq u i t e
controversial; however, more recent controlled trials, includ-
ing those with nifedipine GITS, demonstrated an eﬀective
renal protection as long as blood pressure is also controlled
[37]. In addition, a recently published paper by Nakamura
and colleagues has demonstrated the beneﬁcial eﬀect of a
calcium channel blocker on sRAGE levels in a small cohort
of nondiabetic patients with early-stage kidney disease [38].
Our data are in line with the forementioned study and
have the advantage of having been achieved on a larger
population. The combination of a calcium antagonist and an
angiotensin receptor blocker has a strong rationale and
should be more eﬀective than the monotherapies as demon-
strated in the TALENT study [22].
A limitation of our study is that the assay used to assess
sRAGE levels is unable to distinguish among diﬀerent circu-
lating isoforms of sRAGE. Therefore, since the proportion of
diﬀerent isoforms of sRAGE could diﬀer among individuals,
our study cannot clarify the pathophysiology of the regu-
lation of sRAGE production in patients with and without
microalbuminuria, which would be the subject of a diﬀerent
study.
In conclusion, our study suggests that in high-risk hyper-
tensive patients plasma sRAGE levels do not correlate with
microalbuminuria as long as the GFR is preserved. In this
speciﬁc population, the increase of sRAGE plasma concen-
tration and the reduction of microalbuminuria may indicate
beneﬁts that go beyond blood pressure reduction obtained
by a nifedipine-telmisartan combined treatment.
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